The company offered up more disappointing data for its zinc-finger gene-editing platform.
The company's latest quarterly update is sparking optimism that sales might accelerate.
Why America's most innovative life sciences companies call Alexandria's buildings home and what could be in store next
Positive data from a cohort in a key trial ignited investor optimism.
Shares sold off Wednesday in anticipation of market-moving news.
The company reported a solid launch of its marijuana drug for epilepsy, but sales are going to have to go much higher for it to turn a profit.
Top drug companies addressed sky-high drug prices on Capitol Hill today.
Industry analysts at Jefferies have a very different outlook for two of the most popular pot stocks.
This under-followed Canadian cannabis company is the latest to make the move to the New York Stock Exchange.
Marijuana producers' demand for hydroponic and lighting equipment could jump in 2019.
These companies are opening marijuana dispensaries as fast as they can this year, but that doesn't necessarily make them stocks to buy.
These high-flying companies are rewarding investors with market-beating returns, and there's still time to buy shares.
Disappointing data from Gilead Sciences and Sangamo weigh on investors, while one tiny stock challenges Allergan.
Constellation Brands offered a look into marijuana's future at a key industry conference this week.
Top marijuana stock Tilray is acquiring a little-known pot stock that catapults it into hemp edibles.
Here's what's going on with the world's biggest marijuana stock.
These top pot stocks could be smart buys for long-term growth portfolios this year.
It may make sense to add these Berkshire Hathaway stocks to portfolios this month.
Here's how the first quarter of recreational-marijuana sales in Canada affected these giant marijuana stocks.
An internal look into governance at this marijuana company answers some questions but raises others.